Loomis, Sayles & Company
AVDL

Loomis, Sayles & Company’s Avadel Pharmaceuticals AVDL Stock Holding History

Loomis, Sayles & Company’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-607,323
Closed -$9.91M – 1048
2015
Q3 		$9.91M Buy
+607,323
New +$13.4M 0.03% 426

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Loomis, Sayles & Company's AVDL Position: Q4 2015 in Review

Loomis, Sayles & Company sold out of Avadel Pharmaceuticals (AVDL) in Q4 2015, closing a stake of 607,323 shares — an estimated $9.91M sold.

Loomis, Sayles & Company first reported a position in AVDL in Q3 2015 and held it in 1 quarter. The position peaked at $9.91M in Q3 2015. 89 funds tracked by Wall St. Rank hold AVDL as of Q4 2015.

  • Loomis, Sayles & Company reported no remaining Avadel Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 607,323 Avadel Pharmaceuticals shares in Q4 2015, an estimated $9.91M.
  • Loomis, Sayles & Company first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Loomis, Sayles & Company's Avadel Pharmaceuticals position peaked at $9.91M in Q3 2015.
  • 89 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2015.

Based on Loomis, Sayles & Company's 13F filing for Q4 2015, filed 12 Feb 2016.